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To the Editor; 
A 66-year-old Japanese man presented with a pain-
less skin tumor in his left axillae which had been pres-
ent for several years without receiving any medical 
treatment. The tumor enlarged and lesions appeared 
on several areas on his body within a few months of 
April 2012 (Fig. 1). Histopathological examination of 
a skin biopsy specimen taken from a right inguinal 
tumor showed a dense infiltrate of atypical plasma-
cytoid cells in the dermis and subcutis (Fig. 2). The 
epidermis and papillary dermis were not involved. 
Immunohistological analysis revealed that the tumor 
cells were negative for T- and B-cell surface markers 
CD3, CD4, CD8, CD20, CD56, CD79, and HLA-DR (Fig. 
3), as well as the mature plasma cell and plasma neo-
plasm marker, CD138 (Fig. 3), but were positive for IgG, 
IgG λ light chain, bcl-2 and multiple myeloma onco-
gene-1 (MUM-1) (Fig. 4). Laboratory investigation re-
vealed a small amount of Bence-Jones protein in the 
urine and elevated serum levels of total protein (10.5 
g/dL), creatinine (1.4 mg/dL), calcium (1.4 mg/dL), im-
munoglobulin G (5720 mg/dL), and β2 microglobulin 
(8.1 mg/dL). Chest and abdominal computed tomog-
raphy showed multiple subcutaneous masses; how-
ever, other organs were unaffected. Histopathologi-
cal examination of a bone marrow biopsy specimen 
showed no abnormalities. The diagnosis of primary 
cutaneous plasmacytoma (PCP) was made based on 
the International Myeloma Working Group criteria (1). 
The patient was treated with bortezomib and com-
bined vincristine, doxorubicin, and dexamethasone 
therapy. The tumors initially responded to therapy 
by decreasing in size and temporarily disappearing. 
Several months later, the subcutaneous tumors reap-
peared and enlarged, and the patient subsequently 
died from bleeding from a tumor in the abdomen 14 
months after initial presentation.
Figure 2. Dense, atypical plasma cell infiltrates were 
seen in the dermis and subcutaneous tissues (hema-
toxylin and eosin, ×400). 
Figure 1. Multiple subcutaneous tumors bilaterally 
on the shoulders, chest, and right axilla. 
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Extramedullar plasmacytoma (EMP) is a plasma 
cell tumor that arises outside the bone marrow and 
may occur in the upper respiratory tract, gastrointes-
tinal tract, and central nervous system, but cutane-
ous involvement is rare (1). PCPs constitute approxi-
mately 2–4% of EMP (2). A prognostic difference be-
tween the solitary and multiple forms of the disease 
has been highlighted by some clinicians who pointed 
out that the latter runs a more aggressive course and 
has a relatively high mortality rate, as was seen in our 
patient (3). PCP cells usually express CD79a, CD38, 
and CD138, but are negative for CD20 and leuko-
cyte common antigen. Monotypic expression of IgG 
light chains is usually present (3). In our case, tests 
were negative for CD79 and CD138, but positive for 
MUM-1, bcl-2, and IgG light chain. Bcl-2 is member 
of a family of signaling molecules with proapoptotic 
and anti-apoptotic activities (4). Located in the mito-
chondrial membrane, bcl-2 prevents cell death by in-
hibiting adapter molecules involved in the activation 
of caspases in the intrinsic pathway. Overexpression 
of bcl-2 is found in most human tumor types, and 
is associated with prolonged tumor cell survival, an 
Figure 3. Negative staining of neoplastic cells for 
CD20 (left) and CD138 (right).
Figure 4. The neoplastic cells expressed IgG (top left), IgG λ  light chain (top right), bcl-2 (bottom left) and MUM-
1 (bottom right).
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aggressive clinical course, drug resistance, and a de-
creased survival rate (5). Tumor expression of bcl-2 
and the presence of multiple tumors in the present 
case were associated with a poor prognosis. 
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